



COLORADO
Department of Health Care
Policy & Financing

P & T COMMITTEE MEETING

Agenda

April 5, 2016

1:00 pm – 5:00 p.m.

303 E. 17th Ave, 11th floor conference room, Denver, Colorado

Unfinished Business and General Orders

1. Approval of minutes from the January 5, 2016 P&T Meeting
2. Update on Alzheimer's agents
3. Update on Atypical Antipsychotics
4. Update on Growth Hormones
5. Update on Insulins
6. Update on Intranasal corticosteroids
7. Update on Leukotriene modifiers
8. Update on Multiple Sclerosis agents
9. Update on Ophthalmic allergy agents
10. Update on Sedative/Hypnotics (non-benzodiazepine)
11. Update on Statins/Statin combinations

New Business

- Update from Prior Authorization call center
- Update on Hepatitis C criteria

Drug Classes Up for Review:

- Newer generation antihistamines and antihistamine decongestant combinations
- Angiotensin receptor blockers and combinations
- Renin inhibitors and combinations
- Fibromyalgia agents
- Long acting oral opioids
- Inhaled anticholinergics and combinations
- Inhaled Beta 2 agonists
- Long acting inhaled Beta 2 agonists
- Inhaled corticosteroids and combinations
- Skeletal muscle relaxants
- Testosterone Products
- Topical immunomodulators

Each Review will contain:

- Drug class Overview and Agents up for review for each Drug Class
- Oral presentation by manufacturers, providers, and public following overview
- Committee Discussion and Recommendations for each Class

Upcoming Meeting Date: Tuesday, July 5th or July 12th, 2016; 1:00 p.m. – 5:00 p.m. at 303 E. 17th Ave, 11th floor conference room, Denver, Colorado

Interested parties who want to present at the meeting are encouraged to give advanced notice. Please contact Kelli Metz at 303-866-3982 or by email at Kelli.Metz@state.co.us. Written public comments can be submitted to Kelli.Metz@state.co.us and will be distributed to all present P&T Committee Members.